Establishment Labs Holdings Inc. · NASDAQ:ESTA
Establishment Labs — J.P. Morgan Healthcare Conference 2026
18 slides from Establishment Labs's conference presentation, Jan 14, 2026
Slide 1: Establishment Labs: A Women's Health Company
Motiva | Establishment Establishment Labs pea a? Ea. a FB A Women’s Health Company ARE Peter Caldini (0)
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, pr
Slide 3: Setting the Standard in Breast Aesthetics & Reconstruction
90+ Countries 160+ Publications Patents 218+ | 45 20 Years of Million Devices | Global Innovation Z Setting the Standard in Breast Aesthetics & Reconstruction - < Strong US Growth & Global Momentum — The Future is Motiva Minimally Invasive = = Industry Tailwinds Support Market Growth a = Robust Fina
Slide 4: Unmatched Safety & Performance
nmatched erforman SMOOTHSILK® Enhanced biocompatible surface clinically shown to promote low inflammation and low bacterial attachment TRUEMONOBLOC® Unifies the shell, patch, and gel into a single structure. BLUSEAL® A visual indicator that confirms the barrier layer integrity of the implant for qua
Slide 5: Unmatched Safety & Performance
Unmatched Safety & Performance Motiva® U.S. IDE Study 5-Year Data Primary Augmentation (N=451) Capsular contracture 2-year (95% Cl) 3-year (95% Cl) 4-year (95% Cl) 0.5% (N=2) 0.5% (N=2) 0.5% (N=2) (Baker Grade III/IV) Rupture, suspected or confirmed 0.6% (N=1) 0.6% (N=1) 0.6% (N=1) Breast pain 0.7%
Slide 6: 2025 Accelerating Growth & Profitability
nn eee 2025 Accelerating Growth & Profitability $210.5M - $211.5M Exceptional US Results In First Year 27% _ ‘Full Year Growth $1 7M - 17.5M Motiva® US 4th Quarter Revenue! $64-65M | $75.5M $45.4 - 45.9M 4th Quarter Revenue! Cash Balance! Revenue! Motiva® US Revenue In First Year! Positive Adjusted
Slide 7: Fastest launch in US Breast Aesthetics History
Fastest launch in US Breast Aesthetics History Established a best-in-class organization in 18 months $45.4 - 45.9M Revenue In First Year! ~20% 1500+ Augmentation Accounts Opened Market Share Exiting 2025
Slide 8: One Celebrity Partnership = Growing Market Share
one Celebrity Partnership = Growin Driving 1000+ Patients CQ) Se su Market Share Got Motiva Implants in connection with the Meghan Trainor campaign ews Ano TRENDS RealSelf 2025 Year-End Real Talk Report Mari Malcolm » Nov19, 2025 * 22 minread THE TOP 5 FASTEST-GROWING PROCEDURES 9.2+ Billion Media I
Slide 9: Continuing to Drive Market Share in the US in 2026
Continuing to Drive Market Share in the US in 2026 2026 Q1 Launch Line Extension Motiva Implant ® Sales Rep Expansion Account Growth of Additional Sizes Reconstruction & Adoption Indication Preservé ZMotiva @Motiva Breast Tissue Preservation
Slide 10: Motiva Aesthetic Breast Reconstruction
Motiva Aesthetic Breast Darnn® necon* ¢ Submitted a PMA supplement for Motiva Implants® primary and revision reconstruction indications with FDA in December 2025. Data currently under review with FDA ¢ Motiva Implant approval doubles TAM as recon market is approximately the same size as augmentation
Slide 11: Redefining Breast Surgery: The Motiva Minimally Invasive Platform
Redefining Breast Surgery: The Motiva ® Minimally Invasive Platform ¢ Designed to preserve breast tissue and breast functionality ee . . 5 ¢ Minimal anesthesia required ¢ Small incisions” * Quick recovery’ aQ
Slide 12: Minimally Invasive Procedures: An Untapped Market for Breast Augmentation
Minimally Invasive Procedures An Untapped Market for Breast Augmentation . Appeals to a segment that eee historically has had many barriers ah : to traditional breast augmentation More affluent patients willing to spend for the right benefits
Slide 13: Motiva Minimally Invasive: Driving at least $30M in Revenue in 2026
Motiva® Minimally Invasive Driving at least $30M in Revenue in 2026 mia The New Aesthetics Consumer 29+ Global Markets 144 Mia Centers Multi-Center Clinical Study In First Year Globally Ongoing + 50+ US Early Experience Accounts Trained * More than double from 2024 + 2027 & Beyond * Formal Launch Q1
Slide 14: Market Tailwinds
Market Tailwinds GLP-1 With Even More Powerful GLP-Is on the Horizon, Plastic Surgeons Are Upping the Body Contouring Game + The primary factors that have led women to consider a breast augmentation are body changes including weight loss’ Era of Transparency Celebs Are Finally Being Transparent Abou
Slide 15: Continuous Innovation
Continuous Innovation Driving Growth in 2027 & B US Breast Global Expansion of GEM® Other Reconstruction Minimally Invasive Innovations Platform + Aesthetic Breast + Procedural * Ergonomix2® & Mia Femtech® in the US Reconstruction development * Biosensing + Material sciences
Slide 16: Expect to Grow at Least 25% in 2026 and 2027
Expect to Grow at Least 25% in 2026 and 2027 * Corporate Infrastructure Built Over 20 Years Manufacturing can Supply 50%+ of Global Market * Gross Margins Higher US, MIS, Pipeline, and Commercial Focus * Operating Expenses Growing Well Below Revenue Growth Investment Focused on Advancing in US and M
Slide 17: Powering Sustainable Growth Through Innovation
Slide 18: Establishment Labs
Establishment Labs. ae Ps A Women’s Health Company
Establishment Labs Holdings — J.P. Morgan Healthcare Conference 2026 on 6ix